explore -WSS

explore

author：Wikipedia 2025-09-10 08:41:23 - browse：535

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Secretariat’s lessons for human medicine

Wikipedia

knowledge

WSS

Brain MRIs reveal impact of 'toxic stress' on Black children

Novel spinal cord stimulator treats paralysis without surgery

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

New study raises questions about niacin and heart health

focus

explore

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Researchers tackle phage therapy hurdles for wider adoption

As demand for Covid shots wanes, Moderna seeks its next success

Has Bernie Sanders reached the limit of his pharma bullying effort?

Dobbs anniversary: the lost opportunity of abortion as health care

Chemotherapy before breast cancer surgery might fuel metastasis

Medical records are filled with copy

Crowdfunding for medical bills sidesteps core problem, author says

Supreme Court strikes down use of affirmative action

GSK’s asthma push continues as drug succeeds in Phase 3 trials

hotspot

Brain technologies pose threats that are all too real, experts warn

Measles policy set amid Florida outbreak alarms vaccine proponents

Secretariat’s lessons for human medicine

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Hospitals are piloting generative AI tools as regulators play catch

GSK’s asthma push continues as drug succeeds in Phase 3 trials

leisure time

Wikipedia

knowledge

focus